ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
MannKind Corporation

MannKind Corporation (MNKD)

5.13
0.10
(1.99%)
Closed July 05 4:00PM
5.15
0.02
(0.39%)
After Hours: 6:14PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
5.15
Bid
5.00
Ask
5.16
Volume
1,630,391
4.92 Day's Range 5.14
3.17 52 Week Range 5.75
Market Cap
Previous Close
5.03
Open
5.02
Last Trade
50
@
5.16
Last Trade Time
Financial Volume
$ 8,195,471
VWAP
5.0267
Average Volume (3m)
2,251,161
Shares Outstanding
272,315,846
Dividend Yield
-
PE Ratio
-117.12
Earnings Per Share (EPS)
-0.04
Revenue
198.96M
Net Profit
-11.94M

About MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inh... MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
MannKind Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker MNKD. The last closing price for MannKind was $5.03. Over the last year, MannKind shares have traded in a share price range of $ 3.17 to $ 5.75.

MannKind currently has 272,315,846 shares outstanding. The market capitalization of MannKind is $1.37 billion. MannKind has a price to earnings ratio (PE ratio) of -117.12.

MNKD Latest News

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions

Study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with T1D meeting the primary endpointPatients...

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions

17-week endpoint results comparing Afrezza® head-to-head with multiple daily injections (MDI) and insulin pumpsINHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to...

MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix

Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D spaceNon-cash deal includes royalty-free iSPERSE™ technology license in...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2323-4.31599873665.38235.394.9227764665.13794656CS
40.54511.83496199784.6055.554.3628515525.0224155CS
120.8519.76744186054.35.553.9722511614.66598683CS
261.3936.96808510643.765.553.1726884114.34908169CS
521.1729.39698492463.985.753.1726850374.28124872CS
156-0.25-4.629629629635.45.752.4933310814.15113527CS
2603.99343.9655172411.166.250.833131963.57528032CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BENFBeneficient
$ 4.785
(122.56%)
46.48M
SHOTWSafety Shot Inc
$ 0.33
(83.33%)
1.6k
QLGNQualigen Therapeutics Inc
$ 0.28
(59.64%)
244.69M
INVZWInnoviz Technologies Ltd
$ 0.2499
(51.91%)
17.79k
ZAPPZapp Electric Vehicles Group Ltd
$ 4.06
(49.26%)
50.34M
VEVVicinity Motor Corporation
$ 0.391
(-30.67%)
409.44k
SKYESkye Bioscience Inc
$ 5.495
(-26.34%)
354.28k
CLEUChina Liberal Education Holdings Ltd
$ 2.16
(-24.74%)
13.42M
JZXNJiuzi Holdings Inc
$ 2.60
(-23.53%)
57.7k
WHLRWheeler Real Estate Investment Trust Inc
$ 15.02
(-23.01%)
30.36k
MAXNMaxeon Solar Technologies Ltd
$ 0.2378
(36.98%)
520.76M
QLGNQualigen Therapeutics Inc
$ 0.28
(59.64%)
244.69M
NVDANVIDIA Corporation
$ 125.83
(-1.91%)
214.21M
TSLATesla Inc
$ 251.52
(2.08%)
154.53M
SIRISirius XM Holdings Inc
$ 3.715
(5.24%)
121.14M

MNKD Discussion

View Posts
chrismiss_everyday chrismiss_everyday 1 month ago
MannKind to Establish Boston-Area Research & Development Foothold and Expand Portfolio of Dry Powder Inhalation Technology in Transaction With Pulmatrix

05/29/24

Immediate opportunity to increase capacity for formulation and early asset development in upgraded Boston area R&D space
Non-cash deal includes royalty-free iSPERSE™ technology license in exchange for access to MannKind’s Cricket® inhaler
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has agreed to in-license iSPERSE™ technology from Pulmatrix for certain indications in exchange for an out-license of MannKind’s Cricket® inhaler to Pulmatrix for inhaled delivery of dihydroergotamine (DHE) for migraine treatment. The two companies also agreed that Pulmatrix will transfer its Bedford, Mass. R&D facility to MannKind, along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory in non-cash transaction.

“We are delighted to grow our Boston-area presence as we continue to progress our pipeline efforts, and in particular, our expanding orphan lung programs,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “We have formulated two FDA-approved products utilizing our proven Technosphere® dry powder technology, and this agreement affords us access to another option for future development opportunities.”

“Our Technosphere technology, which is a unique carrier-based, dry powder inhalation platform used in tandem with our proprietary inhaler, provides deep and effective penetration of lung tissue that is well suited for many active ingredients,” said Dr. Burkhard Blank, Executive Vice President, Research & Development and Chief Medical Officer of MannKind Corporation. “However, for some drug candidates, such as Clofazimine, that may require a significantly higher drug payload, the iSPERSE formulation technology may be better suited for developing viable powders.”

The royalty-free licensing structure will allow MannKind to have exclusive use of the iSPERSE technology for clofazimine, NTM, and insulin, and non-exclusive use for endocrine diseases and interstitial lung diseases (ILD) including idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PFF) and other related lung diseases. In exchange, Pulmatrix will receive a royalty-free, exclusive license to MannKind’s single-use Cricket inhalation device for inhaled delivery of DHE in any formulation and non-exclusive use for neurological diseases.

MannKind expects to consolidate its Boston presence by transitioning its Marlborough staff into the newly renovated, fully outfitted R&D facility in Bedford. To maintain continuity of iSPERSE platform knowledge, MannKind plans to hire some members of current Pulmatrix R&D staff.

The agreement is anticipated to close in July 2024.
👍️0
chrismiss_everyday chrismiss_everyday 1 month ago
06/05/24

17-week endpoint results comparing Afrezza® head-to-head with multiple daily injections (MDI) and insulin pumps

INHALE-3 Study Protocol Chair Dr. Irl. B. Hirsh joined by investigational team to deliver presentation moderated by Jaeb Center founder Dr. Roy W. Beck

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced that the 17-week endpoint results from the INHALE-3 study will be presented during a 90-minute symposium and livestream on Saturday, June 22, at the American Diabetes Association’s (ADA) 84th Scientific Sessions. The presentation will be delivered by INHALE-3 Study Protocol Chair Dr. Irl B. Hirsh and the investigational team and will be moderated by Jaeb Center founder Dr. Roy W. Beck.

“We are excited for the first read-out of results from the largest post-market clinical trial MannKind has conducted with Afrezza in the last 10 years,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “The results will speak to the common question about Afrezza: ‘How does inhaled insulin fare when compared head-to-head with usual care?’ The full 30-week results of INHALE-3 will be available later this year.”

Title:
The Efficacy and Safety of Inhaled Insulin Used with Insulin Degludec Compared with Automated Insulin Delivery or Multiple Daily Injections in Adults with Type 1 Diabetes
Date: Saturday, June 22, 2024
Times: 8:00-9:30 AM (ET) with topics/presenters to include:

Inhaled Insulin’s History and Study Rationale – Dr. Halis Akturk

Study Methods & Participant Baseline Characteristics – Dr. Yogish Kudva

Study Results I: Comparison of Inhaled Insulin vs. Rapid Acting Analogue Insulin in Users of AID or

MDI During Standardized In-Clinic Meal Challenge –Dr. Ruth S. Weinstock

Study Results II: Primary Efficacy, Safety, and Quality of Life Outcomes – Dr. Carol J. Levy

Study Results III: Effect of Inhaled Insulin-Degludec Compared with AID and in Subgroups According

to Participant Characteristics – Dr. Grazia Aleppo

Critique of Study Design and Results – by Dr. Irl B. Hirsch

Use of Afrezza in Clinical Practice – by Dr. Thomas Blevins

Question and Answer Session – Moderated by Dr. Roy W. Beck
Location: W320 Chapin Theatre at the Orange County Convention Center (+livestream)
Livestream:
Please refer to https://professional.diabetes.org/scientific-sessions for access details

MannKind will host booth# 1307 in the Exhibit Hall throughout the Scientific Sessions as well. Members of MannKind’s Clinical Education Team will be available for scientific exchange in the medical section of the booth.
👍️0
chrismiss_everyday chrismiss_everyday 1 month ago
https://investors.mannkindcorp.com/news-releases/news-release-details/inhale-3-study-results-be-presented-during-90-minute-symposium
👍️0
Monksdream Monksdream 2 months ago
MNKD under $5
👍️0
chrismiss_everyday chrismiss_everyday 2 months ago
https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-proceed-phase-1-nintedanib-dpi-mnkd-201-study-pulmonary
👍️0
chrismiss_everyday chrismiss_everyday 2 months ago
https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-ind-clearance-us-fda-start-phase-3-study
👍️0
TheFinalCD TheFinalCD 4 months ago
$MNKD 4.65 NEWS MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8 $MNKD https://t.co/R2cKawGGUI— Health Stocks News (@health_stocks) March 5, 2024
👍️ 1
kugel kugel 5 months ago
well just got 6000 more shares thanks
👍️0
chrismiss_everyday chrismiss_everyday 6 months ago
MannKind Corp. said Tuesday it has entered a royalty agreement with Sagard Healthcare under which the latter will receive 1% of royalty sales of Tyvaso DPI inhalation powder for up to $200 million. United Therapeutics Corp. licensed Tyvaso DPI from MannKind in 2018 and started to market it in June 2022 as a treatment for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease following U.S. FDA approval. Under the terms of that deal, MannKind is entitled to a 10% royalty on sales of the treatment. Under its new agreement, Sagard will be entitled to royalty payments equal to 1% of net sales of Tyvaso DPI that are made between Oct. 1, 2023 and Dec. 31, 2042. MannKind will receive a $150 million upfront payment and $50 million if sales equal or exceed $1.9 billion by end-December 2026. If that milestone is not achieved, MannKind will get $45 million if the sales equal or exceed $2.3 billion by Sept. 30 of 2027. If neither milestone is achieved, MannKind will not receive the milestone payment and Sagard will not get any of the royalties payable in respect of sales that exceed $3.5 billion in any calendar year. MannKind’s stock fell 1% premarket and is down 31% over the last 12 months, while the S&P 500 has gained 24%.”
👍️0
kugel kugel 6 months ago
oh wow
👍️ 1
chrismiss_everyday chrismiss_everyday 1 year ago
“On June 26, 2023, MannKind Corporation (the “Company”) was informed that the contract manufacturer responsible for the production of clofazimine inhalation solution, the investigational product being developed by the Company as MNKD-101, experienced a fire in its manufacturing facility in Germany. As a result of this incident, the Company estimates that production of clinical supplies of MNKD-101 will be delayed by 3-6 months, which has the potential to impact the initiation of a Phase 2/3 clinical study of MNKD-101 planned for later in 2023. The Company is evaluating several mitigation strategies and will update the projected timing for this clinical study at a later date.”

Hopefully the clofazimine supply chain has some other nodes available outside of Germany.
https://investors.mannkindcorp.com/node/19231/html
👍️0
chrismiss_everyday chrismiss_everyday 1 year ago
https://imgur.com/a/lTiTEU4

“MannKind Corporation Common Stock is estimated to report earnings on 08/08/2023. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date.”
👍️0
Profit Profit 1 year ago
This is looking real sweet with solid growth and profit coming soon!
👍️ 1
chrismiss_everyday chrismiss_everyday 1 year ago
https://investors.mannkindcorp.com/node/19221/pdf
👍️ 1
chrismiss_everyday chrismiss_everyday 1 year ago
Considering the move into India with Cipla, and the addition of yet another highly qualified team member, it’s looking like some very good years ahead for MannKind.

https://investors.mannkindcorp.com/news-releases/news-release-details/dr-burkhard-blank-joins-mannkind-executive-vice-president
👍️0
chrismiss_everyday chrismiss_everyday 1 year ago
https://investors.mannkindcorp.com/news-releases/news-release-details/correction-mannkind-corporation-reports-2023-first-quarter

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by MannKind Corporation (Nasdaq: MKND), please note in the second table, titled "CONDENSED CONSOLIDATED BALANCE SHEETS", the right column header was incorrectly labeled as "March 31, 2022", when it should be labeled "December 31, 2022". The corrected release follows:

1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022
1Q 2023 Revenues associated with Tyvaso DPI of $23 million
1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million
$167 million of Cash, Cash Equivalents and Investments at March 31, 2023
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the quarter ended March 31, 2023.

“Demand for Tyvaso DPI® has been very strong, which resulted in $23 million in revenues in the first quarter of 2023,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. “I'm excited about our inhaled platform and orphan lung pipeline as we get ready to launch our Phase 2/3 inhaled clofazimine trial for patients in the second half of 2023.”
👍️0
chrismiss_everyday chrismiss_everyday 1 year ago
https://www.insideprecisionmedicine.com/topics/patient-care/therapeutics/respiratory-drugs/new-nanoparticles-carrying-mrna-can-perform-in-lung-gene-editing

Get a lungful of this!
👍️0
Profit Profit 1 year ago
Still long and strong
👍️ 1
chrismiss_everyday chrismiss_everyday 1 year ago
https://www.nasdaq.com/articles/blackrock-updates-holdings-in-mannkind-mnkd
👍️0
chrismiss_everyday chrismiss_everyday 2 years ago
https://www.fool.com/earnings/call-transcripts/2022/11/08/mannkind-corporation-mnkd-q3-2022-earnings-call-tr/
👍️0
chrismiss_everyday chrismiss_everyday 2 years ago
Well…plenty of other good things on the way!

Clofazimine, sold under the brand name Lamprene, is a medication used together with rifampicin and dapsone to treat leprosy. It is specifically used for multibacillary leprosy and erythema nodosum leprosum.

Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.

Dornase alfa is used to reduce the number of lung infections and to improve lung function in patients with cystic fibrosis.

Transforming growth factor-beta (TGFß) is a secreted cytokine, which intricately controls a plethora of physiological and pathological processes during development and carcinogenesis. TGFß exerts antiproliferative effects and functions as a tumor suppressor during early stages of tumorigenesis, whereas at later stages it functions as a tumor promoter aiding in metastatic progression through an autocrine TGFß loop. Intricate knowledge of TGFß signaling and its regulation are still evolving. In this review, we make an attempt to showcase the associated enigma of TGFß signaling in its dual functional role as tumor suppressor and metastatic promoter during early and late stages of carcinogenesis, respectively.
👍️0
chrismiss_everyday chrismiss_everyday 2 years ago
Technosphere® Insulin (TI) peaked 30 minutes faster and significantly reduced postprandial glucose excursions (PPGE) at 60 minutes compared to subcutaneous insulins

The Afrezza with Basal Combination (ABC) Study demonstrated similar glucose control between the three treatment groups; data to be presented and published in 2023
👍️0
chrismiss_everyday chrismiss_everyday 2 years ago
Pretty good news!

“MannKind and United Therapeutics both surge the most in a year after the FDA approved their Tyvaso DPI product for lung disease.”
👍️0
chrismiss_everyday chrismiss_everyday 2 years ago
“Chief Executive Officer, Michael Castagna, PharmD, will ring the opening bell at the Nasdaq stock exchange on Monday, May 23, 2022 at 9:30 am ET at the Nasdaq MarketSite at Times Square.”

Will this also be a day of significant announcement(s)? ??
👍️0
chrismiss_everyday chrismiss_everyday 2 years ago
https://www.go-vgo.com/
👍️0
chrismiss_everyday chrismiss_everyday 2 years ago
https://www.healio.com/news/pulmonology/20220413/transition-to-dry-powder-inhaled-treprostinil-safe-tolerable-for-patients-with-pah
👍️0
chrismiss_everyday chrismiss_everyday 2 years ago
“The FDA is expected to complete its review of the pending NDA for Tyvaso DPI in May 2022.”

Would approval be a jolt to the heart?
👍️0
TheFinalCD TheFinalCD 3 years ago
https://ih.advfn.com/stock-market/NASDAQ/mannkind-MNKD/stock-news/86432282/mannkind-corporation-to-hold-2021-third-quarter-fi
👍️0
terragord7 terragord7 3 years ago
Just realized they had a sales leaseback on the plant in Danbury CT for 100M and it closed in September 2021. Honestly, do not like it too much. That is poor man financing.
👍️0
criqsus criqsus 3 years ago
good info
👍️0
chrismiss_everyday chrismiss_everyday 3 years ago
Improved Bioavailability with Dry Powder Cannabidiol Inhalation: A Phase 1 Clinical Study

https://www.jpharmsci.org/article/S0022-3549(21)00413-5/pdf
👍️0
criqsus criqsus 3 years ago
I came across this stock on seeking alpha. I really look forward to getting paid by this one in my bday in October. GLTA here, Go Mannkind.
👍️0
Profit Profit 3 years ago
Its happening!
👍️0
bakersson bakersson 3 years ago
MNKD partners with NRx Pharmaceuticals

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-partners-nrx-pharmaceuticals-explore-dry-powder

MannKind Partners With NRx Pharmaceuticals To Explore A Dry Powder Formulation Of ZYESAMI™ (aviptadil) Based On The Technosphere® Platform
08/04/21
PDF Version
NRx was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for ZYESAMI™ (aviptadil) for the treatment of Critical COVID-19 with respiratory failure; currently in clinical trials
WESTLAKE VILLAGE, Calif., Aug. 4, 2021 /PRNewswire/ -- MannKind Corporation (Nasdaq: MNKD) has partnered with NRx Pharmaceuticals (Nasdaq: NRXP) (NRx) to evaluate the feasibility of formulating a dry powder formulation of ZYESAMI™ (aviptadil), a synthetic form of human Vasoactive Intestinal Peptide (VIP) – an endogenous substance produced by the body that helps protect cells against inflammatory conditions. An intravenous formulation of ZYESAMI is currently in clinical trials, having been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Critical COVID-19 with Respiratory Failure.

"We continue to explore ways that our Technosphere technology can deliver unique compounds in a targeted and convenient manner for patients with serious lung diseases," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "The novel coronavirus continues to be a factor around the world, and we are just beginning to bear witness to its long-term effects on the lungs."

Rapid recovery from Critical COVID-19 with Respiratory Failure has been reported in patients treated with open label VIP under a Phase 2b/3 clinical trial and in an FDA Expanded Access Program. Emerging data indicates that VIP binds uniquely to receptors on Alveolar Type II cells preventing cell death, stopping replication of the coronavirus in the Type II cells and upregulating the production of surfactant – the loss of which is increasingly implicated in COVID-19 respiratory failure.

"As we continue to identify beneficial effects of VIP in treating various respiratory disorders, development of a convenient dosing method that offers stability at room temperature is key to long term success," said Prof Jonathan Javitt, MD, MPH, CEO and Chairman of the Board, of NRx. "We are pleased to be working with MannKind to develop an inhaled form of ZYESAMI which may offer patients an easier and more therapeutic option."

MannKind will begin exploring formulation potential at its research and manufacturing facility located in Danbury, Conn., which features a full range of development and manufacturing capabilities, including analytical, chemical, formulation, filling and packaging. It has sufficient filling capacity to produce more than 300 million cartridges of inhaled drug annually.

About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled ultra-rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company's partner, Biomm SA. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.

Forward-looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Words such as "plans," "expects," "intend," "will," "targeted," "potential" and similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding the potential to create a dry powder formulation of a new compound and to treat certain diseases. Such forward-looking statements are based upon MannKind's current expectations. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the risk that continued testing of product candidates may not yield successful results. These and other risks are detailed in MannKind's filings with the Securities and Exchange Commission ("SEC"), including under the heading "Risk Factors" in MannKind's Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 12, 2021. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.

ZYESAMI is a trademark of NRx Pharmaceuticals, Inc.

AFREZZA and TECHNOSPHERE are registered trademarks of MannKind Corporation.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mannkind-partners-with-nrx-pharmaceuticals-to-explore-a-dry-powder-formulation-of-zyesami-aviptadil-based-on-the-technosphere-platform-301347875.html

SOURCE MannKind Corporation

For MannKind: Christie Iacangelo, Corporate Communications, (818) 292-3500Email: media@mannkindcorp.com; Rose Alinaya, Investor Relations, (818) 661-5000, Email: ir@mannkindcorp.com; For NRx: Jack Hirschfield, Head of External Affairs, (512) 674-5163, Email: jhirschfield@nrxpharma.com; John Mulally, Investor Relations, (617) 429-3548, Email: jmulally@lifesciadvisors.com

👍️0
Profit Profit 3 years ago
"October"
👍️0
STOCKSEEK STOCKSEEK 3 years ago
Agreed!!!
👍️0
harry crumb harry crumb 3 years ago
Nothing but buying! Patience longs, we will have a big winner here soon enough $$$$
👍️0
harry crumb harry crumb 3 years ago
Great news, look for this to get back to 7+ area in due time. $$$
👍️0
AlphaStockNews AlphaStockNews 3 years ago
$MNKD is screaming for the top after news broke that Medicare patients will have expanded access to Afrezza. https://cnafinance.com/mannkind-mnkd-stock-rokets-on-afrezza-access/
👍️0
Profit Profit 3 years ago
UTHR clearing the road.
Lets Go!
👍️0
AlphaStockNews AlphaStockNews 3 years ago
$MNKD is screaming for the top in the premarket after announcing that its collaboration with United led to an NDA acceptance by the FDA. https://cnafinance.com/mannkind-mnkd-stock-heads-up-on-nda-acceptance/
👍️0
kugel kugel 3 years ago
are there any boards that have new up dates and information.
👍️0
harry crumb harry crumb 3 years ago
They could be landing more use for afrezza with latest studies. This may be a trigger to add in the event things pick up here. $$$
👍️0
Profit Profit 3 years ago
Lets Go!
👍️0
chrismiss_everyday chrismiss_everyday 3 years ago
Easier to read this way...

https://www.sec.gov/edgar/search/#/ciks=0000899460&entityName=MANNKIND%2520CORP%2520(MNKD)%2520(CIK%25200000899460)
👍️0
chrismiss_everyday chrismiss_everyday 3 years ago
“Tired of Pricks?”

https://finance.yahoo.com/news/mannkind-announces-partnership-type-1-130000665.html

Tired of the same old FUD and bash crowd, but there might be a receptive IndyCar audience willing to give Afrezza a try instead of continued injections.
👍️0
chrismiss_everyday chrismiss_everyday 3 years ago
MC- "And we're looking forward to hopefully having an acceptance from the FDA with ILD later this quarter in approval by year end. On the pipeline side, we completed our first toxicology studies for clofazimine, which is MNKD-101."

Looks like leprosy and tuberculosis treatment potential?

"Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as dapsone, for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids.2 Although it carries in vitro activity against other mycobacterium, such as Mycobacterium tuberculosis, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as rifampicin and isoniazid."
👍️0
harry crumb harry crumb 3 years ago
Great report an the stock is red! This schmo joe b.... era is gonna wreck havoc on the stock market
👍️0
bakersson bakersson 3 years ago
I wonder if Tyvaso would help in post covid symptoms.
👍️0
Quaaflac Quaaflac 3 years ago
April 01 press release:
https://ir.unither.com/news/press-releases/press-release-details/2021/United-Therapeutics-Announces-FDA-Approval-and-Launch-of-Tyvaso-for-the-Treatment-of-Pulmonary-Hypertension-Associated-with-Interstitial-Lung-Disease/default.aspx
👍️0

Your Recent History

Delayed Upgrade Clock